TOG Review (RCOG Journal)
MRCOG Part 2
Gynaecological Oncology
Sentinel lymph node mapping in the modern management of gynaecological malignancy
Key Statistics
- <5% — Target false negative rate, SLN mapping
- 25.2% → 1.9% — Lymphoedema: Lymphadenectomy vs SLN (vulval)
- 100% — ICG+Tc99 detection rate, endometrial cancer
Don't-miss facts
-
Target false negative rate for any SLN technique: <5%
-
SLN intraoperative definition: count ratio ≥10:1 vs background; residual basin activity should be <10% of SLN count
-
Blue dye visible window 10–30 min, gone by ~50 min; Tc-99m best detected 1–6 h post-injection (give pre-op)
-
ICG: avoid in iodine allergy/liver dysfunction; contains 5% sodium iodide
-
Vulval SLN standard of care: unifocal, <4 cm, no suspicious groin nodes; midline tumours (≤1 cm) need bilateral detection or side-specific lymphadenectomy
-
Frozen section NOT recommended in cervical (SENTIX) or endometrial (SENTOR/SENTI-ENDO) cancer – poor sensitivity
-
GROINSS-V II: any positive SLN needs further groin treatment; macrometastasis → lymphadenectomy; micrometastasis → radiotherapy is a safe alternative
-
Ultrastaging (serial sectioning + AE1-AE3 IHC) mandatory for SLN processing – detects micrometastases/ITC invisible on standard H&E
Detection rate ranking (best tracer combo)
Endometrial: ICG+Tc-99m 100%, sensitivity 100%, FN 0% Cervical: ICG 98% Vulval: Tc-99m+blue dye 98%
Abbreviation Key
- SLN — sentinel lymph node
- LVSI — lymphovascular space invasion
- ICG — indocyanine green
- SCC — squamous cell carcinoma
- Tc99/Tc-99m — technetium-99m radiolabelled colloid
- FIGO — International Federation of Gynecology and Obstetrics
- NIR — near infrared
- EBRT — external beam radiotherapy
- SPECT-CT — single-photon emission computed tomography–CT
- HR — hazard ratio
- ITC — isolated tumour cell (<0.2 mm deposit)
- RCT — randomised controlled trial
- H&E — haematoxylin and eosin stain
- GOG — Gynecologic Oncology Group
- NPV — negative predictive value
- MSKCC — Memorial Sloan Kettering Cancer Centre
Source: Collins A, Phillips A. Sentinel lymph node mapping in the modern management of gynaecological malignancy. The Obstetrician & Gynaecologist 2023;25:210–219. doi:10.1111/tog.12872
MRCOG AI is an independent educational tool. It is not affiliated with, endorsed by, or connected to the Royal College of Obstetricians and Gynaecologists (RCOG).